• Most Popular
  • Most Shared

Celgene's oral cancer drug gets EU panel recommendation

Fri Mar 23, 2007 12:41pm EDT

Stocks

   

Regulatory News

March 23 (Reuters) - Celgene Corp. (CELG.O) said the European Medicines Agency has recommended the company's oral cancer drug in a combination therapy for multiple myeloma patients who have received at least one treatment earlier.

The recommendation is for use of the drug, Revlimid, in combination with dexamethasone, the company said in a statement.

(Reporting by Hari Kumar in Bangalore)

((Editing by Anil Kumar; Reuters Messaging: hari.kumar.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800 )) Keywords: CELGENE DRUG/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS4824
Regulatory News


More from Reuters

Joint Terminal Attack Controller SSgt Clinton J. Herbison, a U.S. Airman from the 817 Expeditionary Air Support Operations Squadron (EASOS) takes a break during a night mission near Honaker Miracle camp at the Pesh valley of Kunar Province August 12, 2009. Credit: REUTERS/Carlos Barria

Pictures of the Year

A look at the best photos of 2009.  Slideshow 

    PICTURES
    The Dalai Lama jokes with a nasal spray after being asked his opinion on the swine flu during a press conference after his first lecture in Lausanne, Switzerland, August 4, 2009. REUTERS/ Valentin Flauraud

    What a wacky year it's been...

    Um, what's up the Dalai Lama's nose? "Oddly Enough" editor Bob Basler rounds up the goofiest photos of the year.  Full Article 

    Oddly Enough
    A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
    Political Risk in 2010:

    Don't say we didn't warn you

    With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

    Global Markets